Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sotigalimab + nivolumab + ipilimumab
- Development stage
- Unknown
- Lead developer
- Pyxis Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
sotigalimab + nivolumab + ipilimumab is an investigational combination immunotherapy regimen being evaluated for the treatment of advanced cancers. The regimen consists of sotigalimab (APX005M), a humanized monoclonal antibody that acts as an agonist for the CD40 receptor to activate antigen-presenting cells; nivolumab (Opdivo), a monoclonal antibody that inhibits the PD-1 checkpoint; and ipilimumab (Yervoy), a monoclonal antibody that inhibits the CTLA-4 checkpoint. By combining a CD40 agonist with dual checkpoint blockade, the regimen is designed to simultaneously stimulate the innate immune system and remove inhibitory signals on T-cells, potentially overcoming resistance to standard immunotherapy. This specific triplet combination has been studied in Phase 1 investigator-initiated trials led by Yale University for treatment-naive patients with advanced melanoma or renal cell carcinoma (RCC).
- Brand names
- OpdivoYervoy
- Other names
- sotigalimab + nivolumab + ipilimumabAPX005M + nivolumab + ipilimumabA-Yale University-melanoma-renal cell carcinoma
02
Targets
CD40 (Cluster of differentiation 40 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on sotigalimab + nivolumab + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sotigalimab + nivolumab + ipilimumab.